Additive effect of the metabolic syndrome score to the conventional CHADS2 score for the thromboembolic risk stratification of patients with atrial fibrillation

Chia Ti Tsai, Shu Hsuan Chang, Sheng Nan Chang, Juey Jen Hwang, Cho Kai Wu, Yi Chih Wang, Chuen Den Tseng, Huei Ming Yeh, Ling Ping Lai, Fu Tien Chiang, Jiunn Lee Lin

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background The CHA2DS2-VASC scoring scheme may not be better than the CHADS2 scoring scheme in predicting thromboembolic risk for patients with atrial fibrillation (AF) in Asians. Metabolic syndrome is associated with an increased risk of thrombosis. Objective To evaluate whether metabolic syndrome offers incremental information over the CHADS2 scheme in predicting thromboembolic risk for patients with AF in the Taiwanese population. Methods The study population consisted of 721 consecutive patients with AF who had been followed up for a median of 10.8 years. Thromboembolic end points were defined as ischemic stroke/transient ischemic accident and peripheral embolisms. Clinical factors associated with thromboembolic end points were identified by Cox regression analysis. Different scoring systems were compared by receiver operating characteristic (ROC) analysis. Results We found that components in the CHADS2 scheme were associated with an increased risk of thromboembolism. The CHA2DS2-VASC scheme did not provide information additional to that provided by the CHADS 2 scheme on thromboembolism risk (ROC area: 0.670 vs 0.665; P >.05). Metabolic syndrome components were also associated with increased risk of thromboembolism. The incident thromboembolic rate increased incrementally when metabolic syndrome score increased. Additional metabolic syndrome components provide additional information to the CHADS2 scheme on thromboembolism risk (ROC area: 0.670 vs 0.729; P =.034). We therefore proposed a new scoring scheme called CHADS2-MS scoring scheme. In patients with low to intermediate CHADS2 scores (0-1), the use of the CHADS2-MS score may additionally identify patients with high-risk AF for future thromboembolism. Conclusions We, for the first time, demonstrated that metabolic syndrome components were associated with thromboembolic risk in Taiwanese patients with AF. In addition to the conventional CHADS2 scheme, the calculation of the CHADS2-MS score provides additional information on stroke risk assessment.

Original languageEnglish
Pages (from-to)352-357
Number of pages6
JournalHeart Rhythm
Volume11
Issue number3
DOIs
Publication statusPublished - Mar 1 2014
Externally publishedYes

Fingerprint

Atrial Fibrillation
Thromboembolism
ROC Curve
Stroke
Embolism
Population
Accidents
Thrombosis
Regression Analysis

Keywords

  • Atrial fibrillation
  • Metabolic syndrome
  • Stroke
  • Thromboembolism

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Additive effect of the metabolic syndrome score to the conventional CHADS2 score for the thromboembolic risk stratification of patients with atrial fibrillation. / Tsai, Chia Ti; Chang, Shu Hsuan; Chang, Sheng Nan; Hwang, Juey Jen; Wu, Cho Kai; Wang, Yi Chih; Tseng, Chuen Den; Yeh, Huei Ming; Lai, Ling Ping; Chiang, Fu Tien; Lin, Jiunn Lee.

In: Heart Rhythm, Vol. 11, No. 3, 01.03.2014, p. 352-357.

Research output: Contribution to journalArticle

Tsai, Chia Ti ; Chang, Shu Hsuan ; Chang, Sheng Nan ; Hwang, Juey Jen ; Wu, Cho Kai ; Wang, Yi Chih ; Tseng, Chuen Den ; Yeh, Huei Ming ; Lai, Ling Ping ; Chiang, Fu Tien ; Lin, Jiunn Lee. / Additive effect of the metabolic syndrome score to the conventional CHADS2 score for the thromboembolic risk stratification of patients with atrial fibrillation. In: Heart Rhythm. 2014 ; Vol. 11, No. 3. pp. 352-357.
@article{330111cb0428490187a71a68a77cd14f,
title = "Additive effect of the metabolic syndrome score to the conventional CHADS2 score for the thromboembolic risk stratification of patients with atrial fibrillation",
abstract = "Background The CHA2DS2-VASC scoring scheme may not be better than the CHADS2 scoring scheme in predicting thromboembolic risk for patients with atrial fibrillation (AF) in Asians. Metabolic syndrome is associated with an increased risk of thrombosis. Objective To evaluate whether metabolic syndrome offers incremental information over the CHADS2 scheme in predicting thromboembolic risk for patients with AF in the Taiwanese population. Methods The study population consisted of 721 consecutive patients with AF who had been followed up for a median of 10.8 years. Thromboembolic end points were defined as ischemic stroke/transient ischemic accident and peripheral embolisms. Clinical factors associated with thromboembolic end points were identified by Cox regression analysis. Different scoring systems were compared by receiver operating characteristic (ROC) analysis. Results We found that components in the CHADS2 scheme were associated with an increased risk of thromboembolism. The CHA2DS2-VASC scheme did not provide information additional to that provided by the CHADS 2 scheme on thromboembolism risk (ROC area: 0.670 vs 0.665; P >.05). Metabolic syndrome components were also associated with increased risk of thromboembolism. The incident thromboembolic rate increased incrementally when metabolic syndrome score increased. Additional metabolic syndrome components provide additional information to the CHADS2 scheme on thromboembolism risk (ROC area: 0.670 vs 0.729; P =.034). We therefore proposed a new scoring scheme called CHADS2-MS scoring scheme. In patients with low to intermediate CHADS2 scores (0-1), the use of the CHADS2-MS score may additionally identify patients with high-risk AF for future thromboembolism. Conclusions We, for the first time, demonstrated that metabolic syndrome components were associated with thromboembolic risk in Taiwanese patients with AF. In addition to the conventional CHADS2 scheme, the calculation of the CHADS2-MS score provides additional information on stroke risk assessment.",
keywords = "Atrial fibrillation, Metabolic syndrome, Stroke, Thromboembolism, Atrial fibrillation, Metabolic syndrome, Stroke, Thromboembolism",
author = "Tsai, {Chia Ti} and Chang, {Shu Hsuan} and Chang, {Sheng Nan} and Hwang, {Juey Jen} and Wu, {Cho Kai} and Wang, {Yi Chih} and Tseng, {Chuen Den} and Yeh, {Huei Ming} and Lai, {Ling Ping} and Chiang, {Fu Tien} and Lin, {Jiunn Lee}",
year = "2014",
month = "3",
day = "1",
doi = "10.1016/j.hrthm.2013.11.014",
language = "English",
volume = "11",
pages = "352--357",
journal = "Heart Rhythm",
issn = "1547-5271",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Additive effect of the metabolic syndrome score to the conventional CHADS2 score for the thromboembolic risk stratification of patients with atrial fibrillation

AU - Tsai, Chia Ti

AU - Chang, Shu Hsuan

AU - Chang, Sheng Nan

AU - Hwang, Juey Jen

AU - Wu, Cho Kai

AU - Wang, Yi Chih

AU - Tseng, Chuen Den

AU - Yeh, Huei Ming

AU - Lai, Ling Ping

AU - Chiang, Fu Tien

AU - Lin, Jiunn Lee

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Background The CHA2DS2-VASC scoring scheme may not be better than the CHADS2 scoring scheme in predicting thromboembolic risk for patients with atrial fibrillation (AF) in Asians. Metabolic syndrome is associated with an increased risk of thrombosis. Objective To evaluate whether metabolic syndrome offers incremental information over the CHADS2 scheme in predicting thromboembolic risk for patients with AF in the Taiwanese population. Methods The study population consisted of 721 consecutive patients with AF who had been followed up for a median of 10.8 years. Thromboembolic end points were defined as ischemic stroke/transient ischemic accident and peripheral embolisms. Clinical factors associated with thromboembolic end points were identified by Cox regression analysis. Different scoring systems were compared by receiver operating characteristic (ROC) analysis. Results We found that components in the CHADS2 scheme were associated with an increased risk of thromboembolism. The CHA2DS2-VASC scheme did not provide information additional to that provided by the CHADS 2 scheme on thromboembolism risk (ROC area: 0.670 vs 0.665; P >.05). Metabolic syndrome components were also associated with increased risk of thromboembolism. The incident thromboembolic rate increased incrementally when metabolic syndrome score increased. Additional metabolic syndrome components provide additional information to the CHADS2 scheme on thromboembolism risk (ROC area: 0.670 vs 0.729; P =.034). We therefore proposed a new scoring scheme called CHADS2-MS scoring scheme. In patients with low to intermediate CHADS2 scores (0-1), the use of the CHADS2-MS score may additionally identify patients with high-risk AF for future thromboembolism. Conclusions We, for the first time, demonstrated that metabolic syndrome components were associated with thromboembolic risk in Taiwanese patients with AF. In addition to the conventional CHADS2 scheme, the calculation of the CHADS2-MS score provides additional information on stroke risk assessment.

AB - Background The CHA2DS2-VASC scoring scheme may not be better than the CHADS2 scoring scheme in predicting thromboembolic risk for patients with atrial fibrillation (AF) in Asians. Metabolic syndrome is associated with an increased risk of thrombosis. Objective To evaluate whether metabolic syndrome offers incremental information over the CHADS2 scheme in predicting thromboembolic risk for patients with AF in the Taiwanese population. Methods The study population consisted of 721 consecutive patients with AF who had been followed up for a median of 10.8 years. Thromboembolic end points were defined as ischemic stroke/transient ischemic accident and peripheral embolisms. Clinical factors associated with thromboembolic end points were identified by Cox regression analysis. Different scoring systems were compared by receiver operating characteristic (ROC) analysis. Results We found that components in the CHADS2 scheme were associated with an increased risk of thromboembolism. The CHA2DS2-VASC scheme did not provide information additional to that provided by the CHADS 2 scheme on thromboembolism risk (ROC area: 0.670 vs 0.665; P >.05). Metabolic syndrome components were also associated with increased risk of thromboembolism. The incident thromboembolic rate increased incrementally when metabolic syndrome score increased. Additional metabolic syndrome components provide additional information to the CHADS2 scheme on thromboembolism risk (ROC area: 0.670 vs 0.729; P =.034). We therefore proposed a new scoring scheme called CHADS2-MS scoring scheme. In patients with low to intermediate CHADS2 scores (0-1), the use of the CHADS2-MS score may additionally identify patients with high-risk AF for future thromboembolism. Conclusions We, for the first time, demonstrated that metabolic syndrome components were associated with thromboembolic risk in Taiwanese patients with AF. In addition to the conventional CHADS2 scheme, the calculation of the CHADS2-MS score provides additional information on stroke risk assessment.

KW - Atrial fibrillation

KW - Metabolic syndrome

KW - Stroke

KW - Thromboembolism

KW - Atrial fibrillation

KW - Metabolic syndrome

KW - Stroke

KW - Thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84894517202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894517202&partnerID=8YFLogxK

U2 - 10.1016/j.hrthm.2013.11.014

DO - 10.1016/j.hrthm.2013.11.014

M3 - Article

VL - 11

SP - 352

EP - 357

JO - Heart Rhythm

JF - Heart Rhythm

SN - 1547-5271

IS - 3

ER -